THE ILLNESS COMES BEFORE THE COMPARISON
Different health needs require different evidence
Researchers designed these medicines to change different body functions. Human tests found different benefits. Weight lost, fat around organs and relief from lost desire concern different health questions for you.
The uses and risks differ from medicine to medicine
| Medicine | How the body responds | What researchers tested | What approval covers | Possible harms and unanswered questions |
|---|---|---|---|---|
| Semaglutide | copies GLP-1, a hormone helping control hunger and sugar | weight loss and major problems with the heart or with the kidneys [2][3][4] | several prescription uses, with certain products and people | stomach trouble, disease of the gallbladder that stores digestive fluid, a thyroid-tumor warning involving the neck gland controlling energy use, and eye harm from diabetes [5][7] |
| Tirzepatide | copies GIP and GLP-1 to help insulin lower sugar after meals | Phase 3 trials, large treatment tests, against placebo or another drug [1][10][11] | certain diabetes and weight problems and repeated breathing pauses during sleep | stomach trouble, gallbladder illness and a strong warning about thyroid tumors [9][10] |
| Tesamorelin | increases growth hormone and growth-related blood protein | changes in fat buildup in adults with HIV [12][14][16] | reducing unusual fat collecting within the belly with HIV [13] | higher growth-related protein, uncertain cancer risk after long use, and fat returning after treatment [15][16] |
| PT-141 / bremelanotide | changes desire through the brain | two Phase 3 trials, large tests before approval, and continued treatment [19][20] | distressing loss of previously normal desire across partners and settings in women before menopause [21] | nausea, a brief blood-pressure rise and darkened skin patches [20][21] |
Greater weight loss leaves heart and kidney questions open
Tirzepatide adds another hormone action to GLP-1, also copied by semaglutide. SURMOUNT-5 followed 751 adults with obesity for 72 weeks [1]. People getting tirzepatide had greater average weight loss. That doesn't establish greater help for every illness you have; semaglutide has separate trials of major heart and kidney problems [2][3].
Tesamorelin prompts the body to increase growth hormone release. The liver makes more of a protein involved in growth. Trials mainly tested unusual fat buildup in adults with HIV [12][14][16]. Bremelanotide trials instead tested brain changes and distressing loss of desire [18][19].
A lost pound and a prevented heart attack aren't comparable benefits. Nor can belly-fat scans be ranked against women's ratings of desire. You need the question asked in the trial to match the claim. A comparison becomes useful when the people and the illness are clear.
More people help test illness risks while more time tests lasting benefits
Semaglutide has the largest serious-illness trials among the medicines discussed here. SELECT counted major heart problems in 17,604 people [3]. FLOW counted major kidney problems in 3,533 people [2]. Tirzepatide's large weight and sugar trials include tests against semaglutide itself [1][10][11].
Tesamorelin trials concerned unusual belly fat buildup in adults with HIV. A review combined five trials [12]; another trial tested 50 adults [14]. A 52-week study found reduced fat around organs while treatment continued. Fat began returning after treatment stopped [16], leaving no promise of permanent loss.
Bremelanotide research includes treatment trials, follow-up, brain scans and hamster experiments [17][18][19][20]. The Phase 3 trials, large tests before approval, asked about desire and distress. More time in treatment helped researchers check lasting benefit and new harms. You still need a fair comparison and people who have the illness named in the claim.
A new purpose needs evidence even for an approved medicine
FDA review covers a certain medicine for a certain treatment purpose. Approval doesn't expand to every use of the same substance. Tesamorelin's HIV treatment doesn't establish ordinary belly weight loss [13]. Bremelanotide approval excludes male patients, women past menopause or general performance claims [21].
Semaglutide and tirzepatide's wider uses still name certain products and people. A research bottle may have unproven contents despite the familiar drug name, because the name alone can't establish whether the substance is pure or matches the strength of the prescription medicine. PT-141 claims can especially blur prescription bremelanotide with untested research material.
The key question is which illness the approval covers. A doctor may prescribe for another purpose outside the stated approval. Researchers may still be testing that purpose, or evidence may be missing. Your claim needs the medicine, illness and people named plainly to make sense.
A useful treatment comparison includes the harms you could face
Medicines copying GLP-1, the hormone helping control hunger and sugar, commonly cause stomach trouble [5][10][11]. Semaglutide and tirzepatide also raise gallbladder concerns. A tirzepatide review found more gallbladder illness but uncertain pancreas inflammation, swelling in the organ helping digest food and control sugar [9]. A semaglutide diabetes trial found more eye complications from diabetes [7].
Tesamorelin raises growth hormone and a growth-related blood protein. Cancer questions after long use remain, and blood sugar needs checking. LiverTox, a reference explaining drug-related liver harm, judged obvious liver injury unlikely [13][15]. Bremelanotide can cause nausea, headache, briefly raised blood pressure, skin darkening and flushing, warmth and redness of skin [20][21].
An approved medicine comes with drug instructions and continued safety checks. Those checks don't mean you get benefits without possible harm. The drug's risks need weighing alongside the benefits seen in trials. Your health history matters alongside the average for everyone in the trial.